2 results
Approved WMOPending
This Phase 2 study for JNJ-63733657 will assess the possible slowing of cognitive decline seen inprodromal AD and mild AD dementia (Early AD). In addition, effects of JNJ-63733657 on theaccumulation of tau, as measured by tau positron emission…
Approved WMORecruiting
To determine the activity and safety of nivolumab (as monotherapy or in combination with other immunomodulatory treatments) after different immune response induction treatments in TNBC patients with metastatic disease.